CTRI/2022/07/044472
Recruiting
未知
A prospective, open-labelled, multicentre, observational registry of ISAR SUMMIT in CAD patients undergoing PCI in real world indian population (TRANSEVER REGISTRY)
Dr Praveen Chandra0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
- Sponsor
- Dr Praveen Chandra
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female patient with age \> 18 Years
- •2\. Patients with coronary artery disease undergoing percutaneous coronary intervention(PCI) with ISAR Summit Polymer Free Everolimus Eluting Coronary Stent System
- •3\. Patients or legal guardian who understands the study requirements and can provide informed consent in writing
Exclusion Criteria
- •1\. Concurrent participation in another clinical trial that involves an investigational drug or device
- •2\. Participant is pregnant or nursing an infant or child or planning to come pregnant while in the study
- •3\. Concurrent medical condition with a life expectancy of less than 12 months
- •4\. Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or ticagrelor, Everolimus or similar drugs,or any other analogue or derivative, cobalt, chromium or contrast media
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A prospective, open label, multi-centre, observational, post-market study evaluating Juvéderm® Volift with Lidocaine for the correction of moderate to severe nasolabial folds (NLF)gezichtverouderingdermal fillersfacial agingNL-OMON37130Allergan Pharmaceuticals Ireland23
Recruiting
Phase 4
Centralized monitoring study for safety of Traditional Chinese Medicine granulesadverse drug reactionITMCTR2000003180First Affiliated Hospital of Guang zhou University of Chinese Medicine
Active, not recruiting
Not Applicable
A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third lineAdvanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 17.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000491-14-ESAB Science56
Recruiting
Not Applicable
A prospective, multicenter, open-label, observation study evaluating the efficacy and safety of edoxaban in patients with cancer-associated venous thromboembolismKCT0004697Yonsei University Health System, Severance Hospital300
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000491-14-SKAB Science80